Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test plus genetic score may sharpen recurrence prediction in endometrial cancer

NCT ID NCT07681414

Knowledge-focused Sponsor: Guizhou Provincial People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This observational study looks at whether combining a blood test that detects tumor DNA (ctDNA) with a new genetic risk score can better predict if endometrial cancer will come back after surgery. Researchers will follow 52 women who had a hysterectomy for endometrial cancer, collecting blood and tumor tissue for genetic analysis. The goal is to see if this combined approach helps identify who needs more or less aggressive follow-up treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to more personalized treatment decisions for endometrial cancer, helping some patients avoid unnecessary therapy while ensuring others get the intensive care they need.
What could go wrong
This is a small observational study, not a treatment trial. The findings may not change practice without larger, randomized studies to confirm them.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

52 people

The number who actually took part.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study population consists of patients diagnosed with endometrial cancer who underwent radical hysterectomy with bilateral salpingo-oophorectomy and lymph node dissection at Guizhou Provincial People's Hospital, China, between September 2019 and December 2024. All patients had histologically confirmed endometrial cancer and available matched tumor tissue and postoperative plasma samples for NGS and IHC analysis. Patients with stage IV disease or prior neoadjuvant therapy were excluded. The cohort includes FIGO stages I-III, various histologic grades, and all molecular subtypes. A total of 52 patients were enrolled with a median follow-up of 37.5 months.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Female patients aged ≥18 years with histologically confirmed endometrial cancer. 2\. Underwent radical hysterectomy with bilateral salpingo-oophorectomy and lymph node dissection. 3\. Available formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens. 4. Available postoperative peripheral blood samples for plasma ctDNA analysis. 5. Complete clinicopathological data and follow-up records. Exclusion Criteria: * 1\. Patients with stage IV endometrial cancer or distant metastasis at diagnosis. 2\. Patients who received neoadjuvant chemotherapy, radiotherapy, or targeted therapy prior to surgery. 3\. Insufficient or poor-quality tissue or plasma samples for NGS analysis. 4. History of other primary malignancies within the past 5 years (except adequately treated non-melanoma skin cancer or carcinoma in situ). 5\. Incomplete clinical data or loss to follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial cancer

Contacts and locations

Locations

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, 550002, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.